Illuminating the darkness of NMOSD and MOGAD
The Sumaira Foundation is a 501(c)(3) organization dedicated to generating global awareness of neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody associated disorder (MOGAD), creating communities of support for patients and their caregivers, funding research and patient advocacy.
NMOSD is a rare autoimmune disease that affects 10 out of 1 million patients and is oftentimes misdiagnosed as Multiple Sclerosis. The cause is unknown and there is no cure.
Our founding philosophy is that heightened awareness will ultimately lead us towards finding a cure.
To learn more about NMO and the organization, please visit www.sumairafoundation.org
Fundraising, Research, Non-Profit, Awareness, Support, and Charity
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare syndrome that affects the central nervous system as well as the spinal cord.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
Amgen Biotechnology, Biotechnology Research | Amgen Biotechnology, Biotechnology Research | Other 1 Mar 2024 | | |
Roche Pharmaceutical, Biotechnology, Biotechnology Research | Roche Pharmaceutical, Biotechnology, Biotechnology Research | Other 2 Dec 2023 | | |
UCB Pharmaceutical Manufacturing | UCB Pharmaceutical Manufacturing | Other 2 Dec 2023 | | |
Alexion Pharmaceuticals, Inc. Pharmaceutical, Biotechnology, Biotechnology Research | Alexion Pharmaceuticals, Inc. Pharmaceutical, Biotechnology, Biotechnology Research | Other 1 Mar 2024 | | |
AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | Other 15 Nov 2022 | |